文献速递瓣膜病与结构性心脏病心力衰竭与心肌病

白蛋白尿与成人先天性心脏病主要不良结局的关联:波士顿成人先天性心脏病生物样本库结果

Association of Albuminuria With Major Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank.
PubMed 文献 · JAMA Cardiol · 2018-01-01

该前瞻性队列研究纳入612例成人先天性心脏病(ACHD)患者,白蛋白尿(尿白蛋白肌酐比≥30 mg/g)患病率为17.3%。中位随访270天后,白蛋白尿与死亡或非择期心血管住院风险增加相关(HR 3.0),且该关联仅在双心室循环患者中显著,在单心室循环患者中无显著关联。

要点

  • ACHD患者白蛋白尿患病率17.3%,与老龄、糖尿病、低eGFR和发绀相关。
  • 白蛋白尿预测死亡或非择期心血管住院(HR 3.0),也预测死亡(HR 6.4)。
  • 白蛋白尿的风险分层价值仅限于双心室循环患者,NYHA 2级患者中尤为明显。

核心结论

  • 白蛋白尿在ACHD患者中常见,且与双心室循环患者的不良结局风险增加相关。
  • 白蛋白尿可能有助于对NYHA功能分级2级的患者进行风险分层。

研究设计与样本

  • 前瞻性队列研究,纳入2012年5月17日至2016年8月5日在ACHD转诊中心就诊并加入波士顿ACHD生物样本库的612例18岁及以上门诊患者。
  • 白蛋白尿定义为尿白蛋白肌酐比(ACR)≥30 mg/g。
  • 主要结局为死亡或非择期心血管住院(过夜入院,包括心力衰竭、心律失常、血栓栓塞事件、脑出血和/或疾病特异性事件)。

主要发现

  • 白蛋白尿患病率为17.3%(106/612)。
  • 白蛋白尿与年龄较大、糖尿病、较低eGFR和发绀相关。
  • 平均随访270天后,17例(2.5%)死亡,68例(11.1%)死亡或经历非择期住院。
  • 白蛋白尿预测主要结局:30/106(28.3%) vs 38/506(7.5%),HR 3.0(95% CI 1.9-4.9),P < .001。
  • 白蛋白尿与死亡率增加相关:11/106(10.4%) vs 6/506(1.2%),HR 6.4(95% CI 2.4-17.3),P < .001。

关键数值与推荐

  • 白蛋白尿定义:尿白蛋白肌酐比(ACR)≥30 mg/g。
  • 主要结局:死亡或非择期心血管住院(过夜入院,包括心力衰竭、心律失常、血栓栓塞事件、脑出血和/或疾病特异性事件)。

临床怎么用

  • 在ACHD患者中,尤其双心室循环和NYHA功能分级2级患者,检测白蛋白尿有助于风险分层。
  • 白蛋白尿可作为识别高危ACHD患者的简单指标,指导更密切的随访和管理。

局限性

  • 研究样本来自单一转诊中心,可能存在选择偏倚。
  • 随访时间较短(平均270天),事件数较少。
  • 单心室循环患者样本量可能有限,关联不显著需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Albuminuria is associated with adverse outcomes in diverse groups of patients, but the importance of albuminuria in the emerging population of increasingly complex adults with congenital heart disease (ACHD) remains unknown. OBJECTIVE: To assess the prevalence, risk factors, and prognostic implications of albuminuria in ACHD. DESIGN, SETTING, AND PARTICIPANTS: This prospective study assessed a cohort of ambulatory patients aged 18 years and older who were examined at an ACHD referral center and enrolled in the Boston ACHD Biobank between May 17, 2012, to August 5, 2016. Albuminuria was defined as an urine albumin-to-creatinine (ACR) ratio of 30 mg/g or more. MAIN OUTCOMES AND MEASURES: Death or nonelective cardiovascular hospitalization, defined as overnight admission for heart failure, arrhythmia, thromboembolic events, cerebral hemorrhage, and/or disease-specific events. RESULTS: We measured the ACR of 612 adult patients with CHD (mean [SD] age, 38.6 [13.4] years; 308 [50.3%] women). Albuminuria was present in 106 people (17.3%) and was associated with older age (patients with ACR <30 mg/g: mean [SD]: 37.5 [13.2] years; vs patients with ACR ≥30 mg/g: 43.8 [13.1] years; P < .001), presence of diabetes mellitus (ACR <30 mg/g: 13 of 506 [2.6%]; vs ≥30 mg/g: 11 of 106 [10.4%]; P < .001), lower estimated glomerular filtration rate (ACR <30 mg/g: median [interquartile range (IQR)]: 103.3 [90.0-116.4] mL/min/1.73 m2; ACR ≥30 mg/g: 99.1 [78.8-108.7] mL/min/1.73 m2; P = .002), and cyanosis (ACR <30 mg/g: 23 of 506 [5.1%]; vs ACR ≥30 mg/g: 21 of 106 [22.6%]; P < .001). After a mean (SD) follow-up time of 270 (288) days, 17 patients (2.5%) died, while 68 (11.1%) either died or experienced overnight inpatient admission. Albuminuria predicted outcome, with 30 of 106 patients with albuminuria (28.3%) affected vs 38 of 506 patients without albuminuria (7.5%; hazard ratio [HR], 3.0; 95% CI, 1.9-4.9; P < .001). Albuminuria was also associated with increased mortality (11 of 106 [10.4%]; vs 6 of 506 [1.2%] in patients with and without albuminuria, respectively; HR, 6.4; 95% CI, 2.4-17.3; P < .001). Albuminuria was associated with the outcomes only in patients with a biventricular circulation (HR, 4.5; 95% CI, 2.5-8.0) and not those with single-ventricle circulation (HR, 1.0; 95% CI, 0.4-2.8; P = 0.01 compared with biventricular circulation group). Among 133 patients (21.7%) in NYHA functional class 2, albuminuria was strongly associated with death or nonelective hospitalization. CONCLUSIONS AND RELEVANCE: Albuminuria is common and is associated with increased risk for adverse outcome in patients with ACHD with biventricular circulation. Albuminuria appears especially useful in stratifying risk in patients categorized as NYHA functional class 2.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Rajpal S, Alshawabkeh L, Almaddah N, et al. Association of Albuminuria With Major Adverse Outcomes in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank. JAMA Cardiol. 2018. PMID: 29541749. doi:10.1001/jamacardio.2018.0125

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。